BRISBANE, Calif., Jan. 6 InterMune, Inc.(Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief ExecutiveOfficer and President of InterMune, will present at the 27th Annual J.P.Morgan Healthcare Conference in San Francisco on January 15, 2009 at 1:00 p.m.PST.
To access a live audio webcast of the presentation, investors and otherinterested parties may log on to the investor relations page of InterMune'scorporate website at http://www.intermune.com. The company recommends loggingon to the site 15 minutes prior to the start of the presentation in order toregister or download any necessary software.
InterMune is a biotechnology company focused on the research, developmentand commercialization of innovative therapies in pulmonology and hepatology.InterMune has a research and development portfolio addressing idiopathicpulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. Thepulmonology portfolio includes the Phase 3 program, CAPACITY, which isevaluating pirfenidone for the treatment of patients with IPF and a researchprogram focused on small molecules for pulmonary disease. The hepatologyportfolio includes the HCV protease inhibitor compound ITMN-191 (referred toas R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitorresearch program, and a research program evaluating a new target inhepatology. For additional information about InterMune and its R&D pipeline,please visit http://www.intermune.com.
SOURCE InterMune, Inc.